Safety and efficacy of L-carnitine supplementation in patients with hematopoietic stem cell transplantation

Safety and efficacy of L-carnitine supplementation in patients with hematopoietic stem cell transplantation - L-carnitine supplementation for hematopoietic stem cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012424

Enrollment

Registered

2013-11-27

Start date

2013-11-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancy, Bone marrow failure syndrome

Interventions

L-carnitine supplementation No carnitine supplementation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligibility criteria included 20 years of age or older. All patients need possiblility of survival of more than 3 months from the time of registration and written informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria included intake of carnitine in the last two months, carnitine allergy, severe complications, pregnancy, severe mental illness.

Design outcomes

Primary

Measure	Time frame
The change in average fatigue from baseline to day100	—

Countries

Japan

Contacts

Public ContactSatoshi Iyama

Sapporo Medical University School of Medicine Department of Medical Oncology and Hematology

iyama@sapmed.ac.jp011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026